Jennison Associates LLC Boosts Holdings in Qiagen (NYSE:QGEN)

Jennison Associates LLC lifted its stake in shares of Qiagen (NYSE:QGEN) by 5.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,426,392 shares of the company’s stock after purchasing an additional 68,415 shares during the period. Jennison Associates LLC owned about 0.63% of Qiagen worth $65,001,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Nuance Investments LLC lifted its position in Qiagen by 17.3% during the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after buying an additional 778,005 shares in the last quarter. Earnest Partners LLC raised its holdings in shares of Qiagen by 11.1% during the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock worth $156,441,000 after acquiring an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale boosted its position in shares of Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock valued at $133,292,000 after acquiring an additional 353,280 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Qiagen by 62.6% in the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after purchasing an additional 991,325 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Qiagen by 16.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after purchasing an additional 324,417 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on QGEN. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Trading Up 3.2 %

QGEN opened at $42.11 on Thursday. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The business has a fifty day simple moving average of $43.57 and a 200-day simple moving average of $43.73. The firm has a market cap of $9.61 billion, a P/E ratio of 107.97, a P/E/G ratio of 3.16 and a beta of 0.41.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.